MADRIGAL PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$10.56 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-11
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$10.56M, a 147.17% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $10.08M, a 9.06% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $12.22M, a 48.25% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$22.69M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $21.99M, a 9.96% increase from fiscal 2015.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $20.00M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$8.84M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$24.65M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | -$10.56M 10-Q · filed 2017-05-11 | -$480.12K derived: sum of 2 quarters · filed 2017-05-11 | $11.74M derived: sum of 3 quarters · filed 2017-05-11 | -$10.95M derived: sum of 4 quarters · filed 2017-05-11 |
| 2016-12-31 | $10.08M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-31 | $22.30M derived: sum of 2 quarters · filed 2017-03-31 | -$388.73K derived: sum of 3 quarters · filed 2017-03-31 | $21.99M 10-K · filed 2017-03-31 |
| 2016-09-30 | $12.22M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-03-31 | -$10.47M derived: sum of 2 quarters · filed 2017-03-31 | $11.91M 10-Q/A · filed 2017-03-31 | $23.00M derived: sum of 4 quarters · filed 2017-03-31 |
| 2016-06-30 | -$22.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | -$308.00K 10-Q · filed 2016-07-20 | $10.77M derived: sum of 3 quarters · filed 2016-07-20 | $34.39M derived: sum of 4 quarters · filed 2016-07-20 |
| 2016-03-31 | $22.38M 10-Q · filed 2016-05-10 | $33.46M derived: sum of 2 quarters · filed 2016-05-10 | $57.08M derived: sum of 3 quarters · filed 2016-05-10 | $34.06M derived: sum of 4 quarters · filed 2016-07-20 |
| 2015-12-31 | $11.08M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $34.70M derived: sum of 2 quarters · filed 2016-03-15 | $11.68M derived: sum of 3 quarters · filed 2016-07-20 | $20.00M 10-K · filed 2016-03-15 |
| 2015-09-30 | $23.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $601.00K derived: sum of 2 quarters · filed 2016-07-20 | $8.92M 10-Q · filed 2015-11-05 | $7.99M derived: sum of 4 quarters · filed 2016-07-20 |
| 2015-06-30 | -$23.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | -$14.70M 10-Q · filed 2016-07-20 | -$15.63M derived: sum of 3 quarters · filed 2016-07-20 | -$51.21M derived: sum of 4 quarters · filed 2016-07-20 |
| 2015-03-31 | $8.32M 10-Q · filed 2016-05-10 | $7.39M derived: sum of 2 quarters · filed 2016-05-10 | -$28.20M derived: sum of 3 quarters · filed 2016-05-10 | -$16.72M derived: sum of 4 quarters · filed 2016-05-10 |
| 2014-12-31 | -$930.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$36.51M derived: sum of 2 quarters · filed 2016-03-15 | -$25.03M derived: sum of 3 quarters · filed 2016-03-15 | -$8.84M 10-K · filed 2016-03-15 |
| 2014-09-30 | -$35.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$24.10M derived: sum of 2 quarters · filed 2015-11-05 | -$7.91M 10-Q · filed 2015-11-05 | -$23.06M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | $11.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $27.68M 10-Q · filed 2015-08-06 | $12.53M derived: sum of 3 quarters · filed 2016-03-15 | $21.02M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | $16.20M 10-Q · filed 2015-05-07 | $1.05M derived: sum of 2 quarters · filed 2016-03-15 | $9.54M derived: sum of 3 quarters · filed 2016-03-15 | $28.16M derived: sum of 4 quarters · filed 2016-03-15 |
| 2013-12-31 | -$15.15M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$6.66M derived: sum of 2 quarters · filed 2016-03-15 | $11.96M derived: sum of 3 quarters · filed 2016-03-15 | -$24.65M 10-K · filed 2016-03-15 |
| 2013-09-30 | $8.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $27.11M derived: sum of 2 quarters · filed 2014-11-06 | -$9.50M 10-Q · filed 2014-11-06 | -$2.98M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $18.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | -$18.00M 10-Q · filed 2014-08-06 | -$11.48M derived: sum of 3 quarters · filed 2015-03-12 | -$18.32M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | -$36.62M 10-Q · filed 2014-05-08 | -$30.10M derived: sum of 2 quarters · filed 2015-03-12 | -$36.94M derived: sum of 3 quarters · filed 2015-03-12 | -$33.24M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$319.00K derived: sum of 2 quarters · filed 2015-03-12 | $3.38M derived: sum of 3 quarters · filed 2015-03-12 | -$9.94M 10-K · filed 2015-03-12 |
| 2012-09-30 | -$6.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-04 | -$3.14M derived: sum of 2 quarters · filed 2013-11-04 | -$16.46M 10-Q · filed 2013-11-04 | $3.52M derived: sum of 4 quarters · filed 2014-03-11 |
| 2012-06-30 | $3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | -$9.62M 10-Q · filed 2013-08-01 | $10.36M derived: sum of 3 quarters · filed 2014-03-11 | $17.07M derived: sum of 4 quarters · filed 2014-03-11 |
| 2012-03-31 | -$13.32M 10-Q · filed 2013-04-30 | $6.67M derived: sum of 2 quarters · filed 2014-03-11 | $13.37M derived: sum of 3 quarters · filed 2014-03-11 | -$790.00K derived: sum of 4 quarters · filed 2014-03-11 |
| 2011-12-31 | $19.99M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | $26.70M derived: sum of 2 quarters · filed 2014-03-11 | $12.53M derived: sum of 3 quarters · filed 2014-03-11 | $9.33M 10-K · filed 2014-03-11 |
| 2011-09-30 | $6.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$7.46M derived: sum of 2 quarters · filed 2012-11-06 | -$10.66M 10-Q · filed 2012-11-06 | -$11.14M derived: sum of 4 quarters · filed 2013-03-14 |
| 2011-06-30 | -$14.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | -$17.37M 10-Q · filed 2012-08-02 | -$17.85M derived: sum of 3 quarters · filed 2013-03-14 | |
| 2011-03-31 | -$3.20M 10-Q · filed 2012-05-03 | -$3.68M derived: sum of 2 quarters · filed 2013-03-14 | ||
| 2010-12-31 | -$480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | -$19.80M 10-K · filed 2013-03-14 | ||
| 2010-09-30 | -$19.32M 10-Q · filed 2011-11-03 | |||
| 2009-12-31 | $21.05M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |